IDKOF yields 2.52% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 5
Combined, IDKOF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IDKOF + JNJ for your $10,000?
Idemitsu Kosan Co.,Ltd. operates in petroleum, basic chemicals, functional materials, power and renewable energy, and resources businesses in Japan and internationally. The company's Petroleum segment engages in the procurement of crude oil and refining of petroleum products; sale of gasoline, diesel oil, kerosene, automotive lubricants, industrial kerosene, heavy oil, and aviation and marine fuel; and operation of hydrogen stations. Its Basic Chemicals segment manufactures and sells olefins, such as ethylene, propylene, and butadiene; aromatics, including benzene, styrene monomer, mixed xylene, and paraxylene; and other chemicals. The company's Functional Materials segment researches, develops, manufactures, and sells automotive, industrial, and marine lubricants, as well as grease; engineering plastic, adhesive materials, derivative products, and solvents; electronic materials, such as OLED; asphalt; microbial pesticides, soil amendments, and livestock related materials; and solid state lithium ion battery materials. Its Power and Renewable Energy segment operates thermal power plants; develops and operates renewable energy sources, including solar, wind, and biomass power plants; engages in the supply, wholesale, and retail of electric power; researches, develops, and manufactures CIS thin-film solar modules; and sells solar power systems. The company's Resources segments explores, develops, and produces oil and gas; produces and sells coal and uranium; operates geothermal power plants; and sale of electric power and steam. Idemitsu Kosan Co.,Ltd. was founded in 1911 and is headquartered in Tokyo, Japan.
Full IDKOF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.